[{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USFDA Postponds Intercept's NDA Application Meeting for Obeticholic Acid","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ICER Publishes Evidence Report on Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Present New Data from the Interim Analysis of Regenerate Show that Oca Helped Patients with Liver Fibrosis Due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Receives Complete Response Letter From FDA For Obeticholic Acid For the Treatment OF Fibrosis Due To NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New PBC and NASH Data to be Presented at AASLD\u2019s The Liver Meeting Digital Experience\u2122","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from the Interim Analysis of Intercept Pharmaceuticals' REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept to Present New NASH and PBC Data at the Digital International Liver Congress\u2122 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept\u2019s NASH Drug May Need Time to Meet Sky-high Sales Predictions if Approved","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces Withdrawal of EMA Marketing Authorization for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"AllianceRx Walgreens Prime","sponsor":"Duquesne University School of Pharmacy","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AllianceRx Walgreens Prime Studies Use of Ocaliva\u00ae in the Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"AllianceRx Walgreens Prime","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AllianceRx Walgreens Prime \/ Duquesne University School of Pharmacy","highestDevelopmentStatusID":"12","companyTruncated":"AllianceRx.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"$405.0 million","newsHeadline":"Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.45000000000000001,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase IV","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Provides Update on NASH Regulatory Timeline","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces PBC Data Presentations at The International Liver Congress\u2122 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"$405.0 million","newsHeadline":"Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva for PBC Outside the U.S.","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Divestment","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.45000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Intercept Pharmaceuticals \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces Positive Data in Fibrosis Due to NASH From a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis Due to NASH Did Not Meet its Primary Endpoint","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting\u00ae 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Intercept\u2019s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as A Treatment for Pre-Cirrhotic Fibrosis Due To NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Alfasigma","pharmaFlowCategory":"D","amount":"$794.0 million","upfrontCash":"$794.0 million","newsHeadline":"Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0.79000000000000004,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.79000000000000004,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Alfasigma","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Alfasigma","pharmaFlowCategory":"D","amount":"$794.0 million","upfrontCash":"$794.0 million","newsHeadline":"Alfasigma Completes Acquisition of Intercept Pharmaceuticals, Inc.","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0.79000000000000004,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.79000000000000004,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Alfasigma","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva\u00ae (obeticholic acid) for the Treatment of PBC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."}]
Find Clinical Drug Pipeline Developments & Deals for Obeticholic Acid
Details :
Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist, which is being evaluated for the treatment of individuals with primary biliary cholangitis.
Details :
Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate respon...
Details :
Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate respon...
Details :
Ocaliva (obeticholic acid) is a FXR agonist, activating enterocytes and hepatocytes FXRs, thereby reducing toxic levels of bile acids and promoting insulin sensitivity. This results in low risk of lipid deposition into hepatocytes, reducing progression o...
Details :
Ocaliva (obeticholic acid) is a FXR agonist, activating enterocytes and hepatocytes FXRs, thereby reducing toxic levels of bile acids and promoting insulin sensitivity. This results in low risk of lipid deposition into hepatocytes, reducing progression o...
Details :
USFDA has granted orphan drug designation for the combination of ocaliva (obeticholic acid), a farnesoid X receptor agonist and bezafibrate, a PPAR agonist, for the treatment of individuals with primary biliary cholangitis.
Details :
Ocaliva (obeticholic acid) is a FXR agonist, activating enterocytes and hepatocytes FXRs, thereby reducing toxic levels of bile acids and promoting insulin sensitivity. This results in low risk of lipid deposition into hepatocytes, reducing progression o...
Details :
Ocaliva (obeticholic acid) is a FXR agonist, activating enterocytes and hepatocytes FXRs, thereby reducing toxic levels of bile acids and promoting insulin sensitivity. This results in low risk of lipid deposition into hepatocytes, reducing progression o...
Details :
Ocaliva (Obeticholic acid) is a FXR agonist, activating enterocytes and hepatocytes FXRs, thereby reducing toxic levels of bile acids and promoting insulin sensitivity. This results in low risk of lipid deposition into hepatocytes, reducing progression o...
Details :
A pre-specified interim analysis was conducted in 931 subjects who had a liver biopsy at Month 18 to assess the effect of Obeticholic Acid (Ocaliva) on liver histology as compared to baseline biopsies.